Kindred Biosciences, Inc. (KIN) saw a big move last session, as the company’s shares fell by about 28% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for KIN, as the stock is now down 17.9% since July 25.
This slump shouldn’t be too much of a surprise to investors, as this development stage biopharmaceutical company has seen 3 negative revisions in the past few weeks and its current year loss consensus has widened over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
KIN currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the Med-Biomed/Generic industry include Cambrex Corporation. (CBM) , China Biologic Products, Inc. (CBPO) and Epizyme, Inc. (EPZM). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
KINDRED BIOSCIENCES INC (KIN): Free Stock Analysis Report
EPIZYME INC (EPZM): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
CHINA BIOLOGIC PRODUCTS INC (CBPO): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Personal Investing Ideas & Strategies